Skip to main content

Table 4 Effect of avelumab on 89 refined immune cell subsets

From: Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

Post Subset Increase Minimal change Decrease Unadjusted P-value Direction Holm adjusted P-value
1 cycle PD-1+ ICOS+ CD4 12 (63%) 5 (26%) 2 (11%) 0.0181 0.5611
  PD-1+ Tregs 12 (63%) 5 (26%) 2 (11%) 0.0141 0.0705
  Functional intermediate NK 10 (53%) 6 (31%) 3 (16%) 0.0401 0.5213
3 cycles Functional intermediate NK 1 (7%) 4 (29%) 9 (64%) 0.0295 0.4130
9 cycles CTLA-4+ EM CD8 9 (56%) 6 (38%) 1 (6%) 0.0250 0.6250
  Functional intermediate NK 2 (12%) 4 (25%) 10 (63%) 0.0386 0.5018
  PD-1+ pDC 10 (63%) 2 (12%) 4 (25%) 0.0335 0.1005
  CD16+ MDSC 9 (56%) 5 (31%) 2 (13%) 0.0092 0.1288
  gMDSC 11 (69%) 2 (12%) 3 (19%) 0.0131 0.1703
  CD16+ gMDSC 10 (62%) 3 (19%) 3 (19%) 0.0155 0.1705
  PD-1+ lin neg MDSC 10 (62%) 4 (25%) 2 (13%) 0.0182 0.1820
  1. The frequency of 89 refined immune cell subsets was examined pre-therapy and post-1 cycle (n=19), 3 cycles (n=14), and 9 cycles (n=16) of avelumab. Table displays subsets that met criteria as a potentially biologically relevant trend. Results are displayed as the number of patients (percentage of total patients) with an increase of more than 25%, minimal change of less than 25%, and a decrease of more than 25% compared to pre-therapy. Unadjusted p-values (direction of change compared to pre-therapy) were calculated using the Wilcoxon matched-pairs signed rank test, and Holm adjustment was made for the number of subsets within the classic subsets with a frequency above 0.01% of PBMC
  2. EM effector memory, gMDSC granulocytic MDSC, ICOS inducible T cell co-stimulator, lin neg MDSC lineage negative MDSC, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PD-1 programmed cell death protein 1, Tregs regulatory T cells